PROJECT SUMMARY
AlaskaNative and American Indian (ANAI) communities are experiencing a disproportionate share of SARS-
CoV-2 infection and its sequelae in the US. As of September 2021, ANAI people had a cumulative incidence of
9,256 COVID-19 cases per 100,000, compared with 5,445 among non-Hispanic Whites. The current rate of
COVID-19 associated deaths per 100,000 population is 220 among ANAI people, compared with 137 among
non-Hispanic Whites. Widespread vaccination remains the best strategy to control COVID-19 morbidity and
mortality, but the US has one of the lowest vaccine acceptance rates in the world with wide regional variability.
Little research has attempted to understand or address barriers to COVID-19 vaccination in ANAI people,
despite unique geographical, historical, and cultural factors that could influence vaccineuptake in this
population. We have formed a consortium of Tribal health leaders from across Alaska to better understand
vaccine attitudes and intentions, including hesitancy, and to increase vaccineuptake in Alaskan ANAI
communities. In conjunction with community advisors, we will develop and implement a theory-driven
intervention that is grounded in ANAI values of relationality and respect. First, we will use vaccination tracking
data to assess current rates of vaccineuptake and analyze preexisting quantitative and qualitative data
regarding vaccine attitudes, intentions, and behavior among ANAI people in rural and urban areas of Alaska.
We will also conduct a survey in southcentral Alaska to inform intervention design. Second, we will work with
statewide Tribal health leaders and regional Community Advisory Boards to create educational information,
stories, and messages keyed to the beliefs and perceived norms that drive vaccine behavior. This content will
be incorporated into an eHealth toolkit for use by community members and specially trained community
vaccine advocates, laypeople who volunteer to provide information and motivational/emotional support to their
friends, families, and communities. Third, we will launch the intervention in the southcentral region of Alaska
and evaluate effectiveness using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-
AIM) framework. Refinements based on program data and participant feedback will be made, then the refined
intervention will be deployed in two rural regions of Alaska and evaluated. This project will add to the limited
evidence base regarding adult vaccine attitudes, intentions, and behaviors among ANAI people. It holds the
potential to increase vaccination in a hard-hit population and build support for future vaccination as
SARS-CoV2 continues to evolve. Our findings will have broader applicability to vaccine outreach and
engaging ANAI communities in leveraging peer relationships, their social networks, and eHealth to promote
health education and behavior change.
Public Health Relevance Statement
PROJECT NARRATIVE
AlaskaNative and American Indian (ANAI) people in the state of Alaska are twice as likely as the general
population to contract SARS-CoV-2, are at elevated risk for hospitalization and death from COVID-19, and
vaccination remains low. To increase COVID-19 vaccineuptake among ANAI people in Alaska we will train
and support ANAI community members to serve as community vaccine advocates by providing information,
motivational strategies, and Web-based tools to help them talk with vaccine-hesitant friends and family about
COVID-19 vaccines. Broader applicability includes the development of new approaches to vaccine outreach
and engagement in ANAI communities, one that leverages peer relationships, social networks, and eHealth to
promote health education and behavior change.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2019-nCoVAddressAdultAdvocateAgeAlaskaAlaskaNativeAlaskanAmerican Indian PopulationAmerican Indian communityAmerican IndiansAttitudeAwarenessBehaviorBeliefCOVID-19COVID-19 disparityCOVID-19 morbidityCOVID-19 mortalityCOVID-19 vaccinationCOVID-19 vaccineCommunitiesContractsDataDevelopmentEducationEffectivenessEffectiveness of InterventionsEligibility DeterminationEmotionalEnsureEquityEvaluationFamilyFeedbackFriendsFutureGeneral PopulationGeographyGoalsGrainHealthHealth PlanningHealth Promotion and EducationHealth behavior changeHospitalizationIncidenceIndividualInterventionInterviewKnowledgeMotivationNot Hispanic or LatinoParticipantPatternPersonsPopulationPrevalencePublic HealthQualitative MethodsQuasi-experimentRaceReach, Effectiveness, Adoption, Implementation, and MaintenanceReportingResearchRiskRuralSARS-CoV-2 infectionSocial NetworkSurveysTechnologyTestingTrainingUnited StatesUse EffectivenessVaccinatedVaccinationVaccinesWorkcohesioncommunity advisory boardcommunity interventionculturally appropriate interventiondesigneHealtheffectiveness evaluationevidence baseexperiencehealth organizationhuman old age (65+)improvedintervention refinementmembermortalitynovelnovel strategiesoutreachpeerprogramsrural Alaskarural areasocialtheoriestherapy designtooltribal healthuptakeurban areaurban residencevaccine acceptancevaccine distributionvaccine hesitancyvolunteerweb-based tool
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
154870638
UEI
SMQ9D8WCGWY9
Project Start Date
18-August-2022
Project End Date
31-July-2027
Budget Start Date
01-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$648,487
Direct Costs
$598,624
Indirect Costs
$49,863
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$648,487
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI170946-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI170946-03
Patents
No Patents information available for 5R01AI170946-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI170946-03
Clinical Studies
No Clinical Studies information available for 5R01AI170946-03
News and More
Related News Releases
No news release information available for 5R01AI170946-03
History
No Historical information available for 5R01AI170946-03
Similar Projects
No Similar Projects information available for 5R01AI170946-03